Skip to main content

ceftobiprole (Zevtera®)

 

Following non-submission

AWMSG advice

Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, ceftobiprole (Zevtera®) cannot be endorsed for use within NHS Wales for the treatment of the following infections in adults: hospital-acquired pneumonia, excluding ventilator-associated pneumonia; and community-acquired pneumonia. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

 Statement of Advice (SOA): ceftobiprole (Zevtera) 1641 (PDF, 187Kb)

Medicine details

Medicine name ceftobiprole (Zevtera®)
Formulation 500 mg powder for concentrate for solution for infusion
Reference number 1641
Indication

Treatment of the following infections in adults: hospital-acquired pneumonia, excluding ventilator-associated pneumonia; and community-acquired pneumonia. Consideration should be given to official guidance on the appropriate use of antibacterial agents

Company Basilea Pharmaceuticals Ltd
BNF chapter Infections
Assessment type Non-submission
Status Not endorsed (Statement of Advice)
Date of issue 07/05/2014
Follow AWTTC: